Lonza collaborates with AbTis to extend Bioconjugation capabilities
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
India is an example in front of the world to contribute towards strengthening Points of Entry during a public health emergency
The capital expansion program commenced in June 2022 and is expected to complete in 2024
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction
Company is investing more than €100 million in the expansion of the Halle site
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
Subscribe To Our Newsletter & Stay Updated